trending Market Intelligence /marketintelligence/en/news-insights/trending/jvkqmzc2jt0agfi_8axo-w2 content esgSubNav
In This List

UK regulator closes pricing investigation on Concordia's eye treatment


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

UK regulator closes pricing investigation on Concordia's eye treatment

The U.K. Competition and Markets Authority is closing an investigation into Concordia International Corp.'s treatment for an eye disease.

The conjunctivitis treatment, Fusidic Acid eye drops, was one of the company's products that the regulator was investigating after a probe related to the pricing of the company's products was opened in October 2016.

Conjunctivitis is an inflammation or swelling of the conjunctiva, a transparent layer of tissue that lines the inner surface of the eyelid and covers the white part of the eye.

The regulator is also looking into the possibility of competition law infringement in which the company overcharged Britain's National Health Service for an essential thyroid medicine, liothyronine tablets.

Other cases with the U.K. authority include a suspected unfair pricing of hydrocortisone tablets and an alleged collusion with Actavis U.K. to prevent cheaper versions of the medicine from entering the market.

The U.K regulator is also investigating the company's international segment for any breaches of U.K. competition law.